Springer Exploring Pancreatic Metabolism and Malignancy

Product Description This book comprehensively describes the association between metabolic syndrome and pancreatic cancer progression, and the mechanism of action and target definition with a view to drug discovery. Metabolic syndrome, which includes adnominal obesity, hypertension, dyslipidemia, and hyperglycemia, has recently been shown to play an important role in the etiology and progression of various cancers. Further, obesity and diabetes have been associated with an increased incidence of gastric cancers. The book reviews the key biological mechanisms underlying the association between metabolic dysregulation, including obesity-associated enhancement of growth factor signaling, inflammation, and perturbation in pancreatic cancer cell growth and metastasis. It also illustrates the role of the inflammatory signaling pathway in metabolic diseases as well as tumor growth and explores the potential of these pathways as the rational targets for pancreatic cancer therapy. Lastly, the book offers a comprehensive description of the challenges associated with diabetes and pancreatic cancer therapy. From the Back Cover This book comprehensively describes the association between metabolic syndrome and pancreatic cancer progression, and the mechanism of action and target definition with a view to drug discovery. Metabolic syndrome, which includes adnominal obesity, hypertension, dyslipidemia, and hyperglycemia, has recently been shown to play an important role in the etiology and progression of various cancers. Further, obesity and diabetes have been associated with an increased incidence of gastric cancers. The book reviews the key biological mechanisms underlying the association between metabolic dysregulation, including obesity-associated enhancement of growth factor signaling, inflammation, and perturbation in pancreatic cancer cell growth and metastasis. It also illustrates the role of the inflammatory signaling pathway in metabolic diseases as well as tumor growth and explores the potential of these pathways as the rational targets for pancreatic cancer therapy.Lastly, the book offers a comprehensive description of the challenges associated with diabetes and pancreatic cancer therapy. About the Author Dr. Nagaraju GP is a faculty member at the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Nagaraju obtained his M.Sc and Ph.D., both in biotechnology from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. Dr. Nagaraju received his D.Sc. from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju’s research focuses on translational research in gastrointestinal malignancies. He has published over 70 research papers in highly respected international journals and has presented more than 50 abstracts at various national and international conferences. He is author and editor of several. Dr. Nagaraju is an editorial board member of several internationally recognized academic journals, and is an associate member of the Discovery and Developmental Therapeutics research program at Winship Cancer Institute. He is a member of the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), the Science Advisory Board, The RNA Society and the American Association of Cancer Research (AACR). Dr. Aramati BM Reddy is an Assistant Professor at the School of Life Sciences, University of Hyderabad, India. He obtained his Master’s in Biotechnology from SV University, Tirupati-India and Ph.D. from L.V. Prasad Eye Institute, University of Hyderabad, India. He received postdoctoral training at the University of Pennsylvania and University of Texas Medical Branch-Galveston-TX in epigenetics, inflammation, and metabolic disorders. Dr. Reddy’s lab research interests focus on understanding cell signaling and gene regulation in the pathophysiology of metabolic malignancies and glaucoma. His lab is also w